FDA Grants Breakthrough Status to Izalontamab Brengitecan for EGFR-Mutant Lung Cancer

The First FDA-Cleared Blood Test for Alzheimer’s Diagnosis Now Available on the Market

First Patient Enrolled for Aliya® PEF Tumor Ablation of Lung/Liver Soft-Tissue Lesions

FDA Grants Accelerated Approval to Semaglutide for MASH with Liver Fibrosis

mRNA Vaccines Plus Checkpoint Inhibitors Shows Curative Potential in Gastric Cancer

FDA Approves Papzimeos, First Immunotherapy for Recurrent Respiratory Papillomatosis

Breaking the Molecular Link Between Alcohol and Pancreatic Cancer by Targeting CREB

PADCEV–KEYTRUDA Combination Delivers Survival Gains in High-Risk Bladder Cancer

FDA Grants Fast Track Designation to Birelentinib for Relapsed/Refractory CLL and SLL

Epcoritamab + R2 Achieves 95.7% ORR, Cuts Risk by 79% in R/R Follicular Lymphoma

Zongertinib Gains FDA Accelerated Approval for HER2+ NSCLC with 75% ORR

Novel Viral Immunotherapy SuperNova Gains FDA Fast Track Designation for Sarcoma

FDA Fast-Tracks Breyanzi as First CAR T Cell Therapy for Marginal Zone Lymphoma

FDA Approves Modeyso as First-Ever Therapy for Pediatric Brain Tumor, H3 K27M+ Glioma

2025 Pan-Mass Challenge Draws Thousands of Cyclists to Fuel Next Era of Cancer Research

Targeting eIF2A to Halt Melanoma: Study Reveals Key Driver of Cancer Cell Migration

Promising Results: Jaypirca Outperforms Imbruvica in Landmark Phase 3 CLL/SLL Trial

Artificial Sweetener Sucralose May Undermine Cancer Immunotherapy, Study Finds

First Non-Invasive Endometrial Cancer Detection Test, EdenDx, Launched by Gnosis

EMA Grants Orphan Drug Designation to Nuvisertib for Rare Blood Cancer Myelofibrosis

Rewiring Tumor Microenvironment Improved Pancreatic Cancer Treatment

A Mitochondrial Makeover: Rewiring T Cells to Supercharge Cancer Immunotherapy

Obesity-Related Cancer Deaths Triple in the U.S., Raising Alarming Concern

Imfinzi Receives FDA Priority Review as First Immunotherapy for Gastric and GEJ Cancers

From Code to Cure: AI-Designed Proteins Arm T Cells to Precisely Target Cancer

START and Advarra Unite to Streamline Early-Phase Oncology Trials with Speed

Shane Jacobson Appointed CEO of the American Cancer Society

Leadership Change at V Foundation, Clark Kinlin Appointed Interim CEO

START Hope Hub Connect Patients and Physicians with Faster, Smarter Trial Access

Darolutamide Shows Significant Quality-of-Life Improvements in mCS Prostate Cancer

ATOMIC Trial: Atezolizumab Combo Halves Recurrence in Stage III dMMR Colon Cancer

Targeted ADC ZL-1310 Shows Promising 67% ORR in Heavily Pretreated ES-SC Lung Cancer

Darzalex Faspro Achieves Outstanding Results in Multiple Myeloma with 95% 4-Year PFS

AI-Driven bioX Genetics Platform Slashes Genetic Variant Detection Time

Vividion and Bayer Advance First-in-Class WRN Inhibitor VVD-214 for Solid Tumors

IMforte Study: Tecentriq Plus Lurbinectedin Extends Survival in ES-SC Lung Cancer

OASIS-4 Trial: Elinzanetant Reduces Hot Flashes in Breast Cancer Treatment

BioNTech and BMS Forge Partnership to Advance BNT327 for Solid Tumors

Pasritamig’s Favorable Safety and Efficacy in Advanced Prostate Cancer

Imdelltra Extends Survival in Small Cell Lung Cancer, Cutting Death Risk by 40%

Libtayo Demonstrates 68% Risk Reduction in High-Risk CS Cell Carcinoma

Inavolisib Combination Doubles PFS in PIK3CA Mutated Advanced Breast Cancer

The Latest Issue of ONCOLife Is Now Live – Follow the Cutting Edge of Oncology Innovation

START and OneOncology Partnership Expands Clinical Trials from Academia to Community

DNA-Based Immunotherapy IMNN-001 Shows Survival Gains in Advanced Ovarian Cancer

MB-105 CAR-T Therapy: Advancing Precision Treatment for CD5+ T-Cell Lymphoma

EU Commission Approves Opdivo Regimen for High-Risk Resectable NSCLC

FDA Approves First Blood Test for Alzheimer’s, Marking a Historic Shift in Early Detection

START Doses First Patient in Trial of mRNA-4106, a Pan-Tumor Therapy for Solid Tumors

FDA Approves Emrelis as the First Targeted ADC for High c-Met Expressing Lung Cancer